A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics

Clinical Proteomics

Amy PN Skubitz²  Stefan E Pambuccian³  Timothy J Griffin⁴  Kayla Hickey²  Melissa A Geller¹  Somaieh Afiuni-Zadeh²  Kristin LM Boylan² 

[1] Department of Obstetrics, Gynecology, and Women’s Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA;Department of Laboratory Medicine and Pathology, University of Minnesota, MMC 395, 420 Delaware St. S.E., Minneapolis, MN 55455, USA;Department of Pathology, Loyola University Medical Center, Chicago, IL, USA;Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, USA

关键词: Biomarker discovery;    Pap test;    Proteomics;    Mass spectrometry;   

Others  :  1026167
DOI  :  10.1186/1559-0275-11-30

 received in 2013-12-20, accepted in 2014-05-21,  发布年份 2014

【 摘 要 】

Background

The proteomic analysis of body fluids is a growing technology for the identification of protein biomarkers of disease. Given that Papanicolaou tests (Pap tests) are routinely performed on over 30 million women annually in the U.S. to screen for cervical cancer, we examined the residual Pap test fluid as a source of protein for analysis by mass spectrometry (MS). In the liquid-based Pap test, cervical cells are collected from the ectocervix and placed into an alcohol-based fixative prior to staining and pathologic examination. We hypothesized that proteins shed by cells of the female genital tract can be detected in the Pap test fixative by MS-based proteomic techniques. We examined the feasibility of using residual fluid from discarded Pap tests with cytologically “normal” results to optimize sample preparation for MS analysis. The protein composition of the cell-free Pap test fluid was determined by silver staining of sodium dodecyl sulfate -polyacrylamide gels, and the abundance of serum proteins was examined by Western immunoblot using an antibody against human serum albumin. Both pooled and individual samples were trypsin digested and analyzed by two-dimensional MS/MS. Proteins were identified by searching against the Human Uniprot database, and characterized for localization, function and relative abundance.

Results

The average volume of the residual Pap test fluid was 1.5 ml and the average protein concentration was 0.14 mg/ml. By Western immunoblot we showed that the amount of albumin in each sample was significantly reduced compared to normal serum. By MS/MS, we identified 714 unique proteins in pooled Pap test samples and an average of 431 proteins in individual samples. About 40% of the proteins identified were extracellular or localized to the plasma membrane. Almost 20% of the proteins identified were involved in immunity and defense, characteristic of the healthy cervical-vaginal proteome. By merging the protein sets from the individual and pooled Pap test samples, we created a “Normal Pap test Core Proteome” consisting of 153 proteins.

Conclusions

Residual Pap test fluid contains a sufficient amount of protein for analysis by MS and represents a valuable biospecimen source for the identification of protein biomarkers for gynecological diseases.

【 授权许可】

   
2014 Boylan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Koss LG: The Papanicolaou test for cervical cancer detection. A triumph and a tragedy. JAMA 1989, 261:737-743.
• [2]Linder J, Zahniser D: The ThinPrep Pap test. A review of clinical studies. Acta Cytol 1997, 41:30-38.
• [3]Howell LP, Davis RL, Belk TI, Agdigos R, Lowe J: The AutoCyte preparation system for gynecologic cytology. Acta Cytol 1998, 42:171-177.
• [4]Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH: Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994, 271:1866-1869.
• [5]Becton Dickinson: BD SurePathTM preservative fluid material safety data sheet. Franklin Lakes, NJ: Becton Dickinson; 2011. [Catalog number 490527]
• [6]Hologic: ThinPrep PreservCyt solution material safety data sheet. Bedford, MA: Hologic, Inc; 2010. P/N-85093 Rev. 001
• [7]DeMay RM: Cytopathology of false negatives preceding cervical carcinoma. Am J Obstet Gynecol 1996, 175:1110-1113.
• [8]Eltoum IA, Roberson J: Impact of expected changes in national papanicolaou test volume on the cytotechnology labor market: an impending crisis. Am J Clin Pathol 2007, 128:665-670.
• [9]Sirovich BE, Welch HG: The frequency of Pap smear screening in the United States. J Gen Intern Med 2004, 19:243-250.
• [10]Zegels G, Van Raemdonck GA, Tjalma WA, Van Ostade XW: Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. Proteome Sci 2010, 8:63.
• [11]Shaw JL, Smith CR, Diamandis EP: Proteomic analysis of human cervico-vaginal fluid. J Proteome Res 2007, 6:2859-2865.
• [12]Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R: Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010, 34:1407-1416.
• [13]Zegels G, Van Raemdonck GA, Coen EP, Tjalma WA, Van Ostade XW: Comprehensive proteomic analysis of human cervical-vaginal fluid using colposcopy samples. Proteome Sci 2009, 7:17.
• [14]Tang LJ, De Seta F, Odreman F, Venge P, Piva C, Guaschino S, Garcia RC: Proteomic analysis of human cervical-vaginal fluids. J Proteome Res 2007, 6:2874-2883.
• [15]Pereira L, Reddy AP, Jacob T, Thomas A, Schneider KA, Dasari S, Lapidus JA, Lu X, Rodland M, Roberts CT Jr, Gravett MG, Nagalla SR: Identification of novel protein biomarkers of preterm birth in human cervical-vaginal fluid. J Proteome Res 2007, 6:1269-1276.
• [16]Panicker G, Ye Y, Wang D, Unger ER: Characterization of the human cervical mucous proteome. Clin Proteomics 2010, 6:18-28.
• [17]Klein LL, Jonscher KR, Heerwagen MJ, Gibbs RS, McManaman JL: Shotgun proteomic analysis of vaginal fluid from women in late pregnancy. Reprod Sci 2008, 15:263-273.
• [18]Gravett MG, Thomas A, Schneider KA, Reddy AP, Dasari S, Jacob T, Lu X, Rodland M, Pereira L, Sadowsky DW, Roberts CT Jr, Novy MJ, Nagalla SR: Proteomic analysis of cervical-vaginal fluid: identification of novel biomarkers for detection of intra-amniotic infection. J Proteome Res 2007, 6:89-96.
• [19]Di Quinzio MK, Oliva K, Holdsworth SJ, Ayhan M, Walker SP, Rice GE, Georgiou HM, Permezel M: Proteomic analysis and characterisation of human cervico-vaginal fluid proteins. Aust N Z J Obstet Gynaecol 2007, 47:9-15.
• [20]Dasari S, Pereira L, Reddy AP, Michaels JE, Lu X, Jacob T, Thomas A, Rodland M, Roberts CT Jr, Gravett MG, Nagalla SR: Comprehensive proteomic analysis of human cervical-vaginal fluid. J Proteome Res 2007, 6:1258-1268.
• [21]Di Quinzio MK, Georgiou HM, Holdsworth-Carson SJ, Ayhan M, Heng YJ, Walker SP, Rice GE, Permezel M: Proteomic analysis of human cervico-vaginal fluid displays differential protein expression in association with labor onset at term. J Proteome Res 2008, 7:1916-1921.
• [22]Gu Y, Wu SL, Meyer JL, Hancock WS, Burg LJ, Linder J, Hanlon DW, Karger BL: Proteomic analysis of high-grade dysplastic cervical cells obtained from ThinPrep slides using laser capture microdissection and mass spectrometry. J Proteome Res 2007, 6:4256-4268.
• [23]Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, et al.: The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004, 32:D258-D261.
• [24]Mi H, Muruganujan A, Thomas PD: PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013, 41:D377-D386.
• [25]Piehowski PD, Petyuk VA, Orton DJ, Xie F, Moore RJ, Ramirez-Restrepo M, Engel A, Lieberman AP, Albin RL, Camp DG, Smith RD, Myers AJ: Sources of technical variability in quantitative LC-MS proteomics: human brain tissue sample analysis. J Proteome Res 2013, 12:2128-2137.
• [26]Gan CS, Chong PK, Pham TK, Wright PC: Technical, experimental, and biological variations in isobaric tags for relative and absolute quantitation (iTRAQ). J Proteome Res 2007, 6:821-827.
• [27]Paoletti AC, Parmely TJ, Tomomori-Sato C, Sato S, Zhu D, Conaway RC, Conaway JW, Florens L, Washburn MP: Quantitative proteomic analysis of distinct mammalian Mediator complexes using normalized spectral abundance factors. Proc Natl Acad Sci U S A 2006, 103:18928-18933.
• [28]Zybailov B, Mosley AL, Sardiu ME, Coleman MK, Florens L, Washburn MP: Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. J Proteome Res 2006, 5:2339-2347.
• [29]Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005, 175:7560-7567.
• [30]Andersch-Bjorkman Y, Thomsson KA, Holmen Larsson JM, Ekerhovd E, Hansson GC: Large scale identification of proteins, mucins, and their O-glycosylation in the endocervical mucus during the menstrual cycle. Mol Cell Proteomics 2007, 6:708-716.
• [31]Nemes Z, Steinert PM: Bricks and mortar of the epidermal barrier. Exp Mol Med 1999, 31:5-19.
• [32]Moll R, Levy R, Czernobilsky B, Hohlweg-Majert P, Dallenbach-Hellweg G, Franke WW: Cytokeratins of normal epithelia and some neoplasms of the female genital tract. Lab Invest 1983, 49:599-610.
• [33]Steinau M, Patel SS, Unger ER: Efficient DNA extraction for HPV genotyping in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 2011, 13:377-381.
• [34]Keegan H, Boland C, Malkin A, Griffin M, Ryan F, Lambkin H: Comparison of DNA extraction from cervical cells collected in PreservCyt solution for the amplification of Chlamydia trachomatis. Cytopathology 2005, 16:82-87.
• [35]Gilbert L, Oates E, Ratnam S: Stability of cervical specimens in SurePath medium for human papillomavirus testing with the Roche cobas 4800 assay. J Clin Microbiol 2013, 51:3412-3414.
• [36]Agreda PM, Beitman GH, Gutierrez EC, Harris JM, Koch KR, LaViers WD, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, Palmer ML, Porter MJ, Richart GA, Schwab RJ, Vaughan LM: Long-term stability of human genomic and human papillomavirus DNA stored in BD SurePath and Hologic PreservCyt liquid-based cytology media. J Clin Microbiol 2013, 51:2702-2706.
• [37]Cole AM: Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006, 306:199-230.
• [38]Quayle AJ: The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J Reprod Immunol 2002, 57:61-79.
• [39]Laudadio J: Human papillomavirus detection: testing methodologies and their clinical utility in cervical cancer screening. Adv Anat Pathol 2013, 20:158-167.
• [40]SEER Cancer Statistics Factsheets: Ovary Cancer Bethesda, MD: National Cancer Institute; http://seer.cancer.gov/statfacts/html/ovary.html webcite
• [41]Schwamborn K, Krieg RC, Uhlig S, Ikenberg H, Wellmann A: MALDI imaging as a specific diagnostic tool for routine cervical cytology specimens. Int J Mol Med 2011, 27:417-421.
• [42]Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih Ie M, Kurman R, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman JR, Carvalho JP, Marie SK, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA Jr: Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013, 5:167. ra164
• [43]Blum H, Beier H, Gross HJ: Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 1987, 8:93-99.
• [44]Andersen JD, Boylan KL, Xue FS, Anderson LB, Witthuhn BA, Markowski TW, Higgins L, Skubitz AP: Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 2010, 31:599-610.
• [45]de Jong EP, van Riper SK, Koopmeiners JS, Carlis JV, Griffin TJ: Sample collection and handling considerations for peptidomic studies in whole saliva; implications for biomarker discovery. Clin Chim Acta 2011, 412:2284-2288.
• [46]Wisniewski JR, Zielinska DF, Mann M: Comparison of ultrafiltration units for proteomic and N-glycoproteomic analysis by the filter-aided sample preparation method. Anal Biochem 2011, 410:307-309.
• [47]Yang F, Shen Y, Camp DG 2nd, Smith RD: High-pH reversed-phase chromatography with fraction concatenation for 2D proteomic analysis. Expert Rev Proteomics 2012, 9:129-134.
• [48]Lin-Moshier Y, Sebastian PJ, Higgins L, Sampson ND, Hewitt JE, Marchant JS: Re-evaluation of the role of calcium homeostasis endoplasmic reticulum protein (CHERP) in cellular calcium signaling. J Biol Chem 2013, 288:355-367.
• [49]Keller A, Nesvizhskii AI, Kolker E, Aebersold R: Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002, 74:5383-5392.
• [50]Nesvizhskii AI, Keller A, Kolker E, Aebersold R: A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003, 75:4646-4658.
• [51]Elias JE, Gygi SP: Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods 2007, 4:207-214.